ANCHOR CRC: Triple therapy combo improves ORR in BRAF V600E-mutant mCRC
09 Sep 2020
bởiElaine Soliven
The combination of encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) improves objective response rate (ORR) in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) in the first-line setting, according to the ANCHOR CRC* trial presented at ESMO GI 2020.
